Komei Yanase1, Norihiko Funaguchi2, Hirotoshi Iihara3, Maya Yamada3, Daizo Kaito1, Junki Endo1, Fumitaka Ito1, Yasushi Ohno1, Hidekazu Tanaka4, Yoshinori Itoh3, Shinya Minatoguchi1. 1. Department of Cardiology and Respirology and Nephrology, Gifu University Graduate School of Medicine Japan. 2. Department of Cardiology and Respirology and Nephrology, Gifu University Graduate School of Medicine Japan ; Department of Respiratory Medicine, Murakami Memorial Hospital, Asahi University Japan. 3. Department of Pharmacy, Gifu University Hospital Japan. 4. Department of Radiology, Gifu University Hospital Japan.
Abstract
BACKGROUND: Concurrent chemoradiotherapy (CCRT) plays an important role in multimodality therapy for non-small cell lung cancer. However, esophagitis often develops as a complication of CCRT, causing treatment delays and reducing the patient's quality of life. We examined the efficacy of polaprezinc (PZ), zinc L-carnosine used for the therapy of gastric ulcer, against the onset of esophagitis caused by CCRT for lung cancer. PATIENTS AND METHODS: Patients who concurrently underwent chemotherapy with carboplatin and paclitaxel and thoracic radiotherapy at Gifu University Hospital during a period of January 2011 and May 2015 were the subjects of the present study. Patients received a mixture of sodium alginate solution and aluminum-magnesium hydroxide gel with (PZ group) or without (control group) PZ for prevention of radiation esophagitis. RESULTS: PZ significantly inhibited the development of grade ≥2 radiation esophagitis (HR 0.397, 95% confidence interval, 0.160-0.990; P=0.047). In addition, PZ lowered the incidence of grade ≥2 esophagitis at the time point of 40 Gy irradiation (26.3% versus 63.2%, P=0.05). However, there were no significant differences in the incident rates of other adverse events associated with chemoradiotherapy between the PZ group and control group. Moreover, PZ had no significant influence on the tumor response rate. CONCLUSION: PZ significantly retarded the development as well as the incidence of grade ≥2 esophagitis without affecting the tumor response.
BACKGROUND: Concurrent chemoradiotherapy (CCRT) plays an important role in multimodality therapy for non-small cell lung cancer. However, esophagitis often develops as a complication of CCRT, causing treatment delays and reducing the patient's quality of life. We examined the efficacy of polaprezinc (PZ), zinc L-carnosine used for the therapy of gastric ulcer, against the onset of esophagitis caused by CCRT for lung cancer. PATIENTS AND METHODS: Patients who concurrently underwent chemotherapy with carboplatin and paclitaxel and thoracic radiotherapy at Gifu University Hospital during a period of January 2011 and May 2015 were the subjects of the present study. Patients received a mixture of sodium alginate solution and aluminum-magnesium hydroxide gel with (PZ group) or without (control group) PZ for prevention of radiation esophagitis. RESULTS: PZ significantly inhibited the development of grade ≥2 radiation esophagitis (HR 0.397, 95% confidence interval, 0.160-0.990; P=0.047). In addition, PZ lowered the incidence of grade ≥2 esophagitis at the time point of 40 Gy irradiation (26.3% versus 63.2%, P=0.05). However, there were no significant differences in the incident rates of other adverse events associated with chemoradiotherapy between the PZ group and control group. Moreover, PZ had no significant influence on the tumor response rate. CONCLUSION: PZ significantly retarded the development as well as the incidence of grade ≥2 esophagitis without affecting the tumor response.
Authors: Mitchell Machtay; Chuanchieh Hsu; Ritsuko Komaki; William T Sause; R Suzanne Swann; Corey J Langer; Roger W Byhardt; Walter J Curran Journal: Int J Radiat Oncol Biol Phys Date: 2005-05-31 Impact factor: 7.038
Authors: H Adachi; K Ono; M Abe; T Inoue; T Imura; Y Onoyama; Y Tanaka; I Narabayashi; Y Yoshikawa Journal: Nihon Gan Chiryo Gakkai Shi Date: 1985-04-20
Authors: Alfonso Vidal-Casariego; Alicia Calleja-Fernández; María D Ballesteros-Pomar; Isidoro Cano-Rodríguez Journal: Nutr Cancer Date: 2013 Impact factor: 2.900
Authors: Ana Sofia Spencer; David da Silva Dias; Manuel Luís Capelas; Francisco Pimentel; Teresa Santos; Pedro Miguel Neves; Antti Mäkitie; Paula Ravasco Journal: Front Oncol Date: 2021-11-22 Impact factor: 6.244